JAK1 and COVID-19: In general, the use of ruxolitinib has been authorized in COVID-19 patients with respiratory insufficiency, and clinical evidence has suggested that this inhibitor of JAK1 and JAK2 can reduce inflammatory pulmonary reaction and potentially prevent the use of intensive care.